Dravet syndrome drug development pipeline review 2019

It has been a year since we released the 2018 Dravet Syndrome Pipeline and Opportunities Review, a market research publication that provides an overview of the global therapeutic landscape of Dravet syndrome.

In the last 12 months the pipeline has changed by, among others, the approval by the FDA of Diacomit (stiripentol), the CHMP positive opinion on Epidyolex (cannabidiol) approval, the IPO from Stoke Therapeutics and the arrival of a new company pursuing a gene therapy approach for Dravet syndrome (Encoded Therapeutics).

The 2019 Dravet Syndrome Pipeline and Opportunities Review provides a review and analysis of 12 drug candidates in development for the treatment of Dravet syndrome, including 11 products that have received orphan drug designations.

The Report includes the most recent updates on programs from GW Pharmaceuticals (Epidiolex / Epidyolex), Zogenix (Fintepla, ZX008), Biocodex (stiripentol) , Ovid Therapeutics (Soticlestat, OV935, TAK-935), Takeda Pharmaceutical, Supernus Pharmaceuticals (SPN-817, Huperzine), Xeris Pharmaceutical (diazepam), Epygenix Therapeutics (EPK-100, -200 and -300), NeuroCycle Therapeutics (NCT10015), PTC Therapeutics (ataluren), Stoke Therapeutics (STK-001), Encoded Therapeutics and OPKO Health (OPK88001, CUR-1915).

The 2019 Dravet Syndrome Pipeline and Opportunities Review also includes an analysis of the competitive landscape, unmet needs, and evaluates current and future opportunities of the Dravet syndrome market.

The report is now available in this site.